Ventyx Biosciences (NASDAQ:VTYX) Earns “Neutral” Rating from HC Wainwright

Ventyx Biosciences (NASDAQ:VTYX)‘s stock had its “neutral” rating reissued by investment analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports.

Separately, Oppenheimer reaffirmed an “outperform” rating and set a $9.00 price target (down from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Ventyx Biosciences Stock Up 0.5 %

Shares of NASDAQ VTYX traded up $0.01 during trading on Tuesday, hitting $1.96. 554,183 shares of the company traded hands, compared to its average volume of 2,130,565. Ventyx Biosciences has a 1 year low of $1.67 and a 1 year high of $11.48. The company has a 50-day moving average price of $2.29 and a 200-day moving average price of $2.28. The firm has a market capitalization of $138.59 million, a P/E ratio of -0.83 and a beta of 0.55.

Insiders Place Their Bets

In other news, insider John Nuss sold 21,119 shares of the company’s stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $2.36, for a total value of $49,840.84. Following the sale, the insider now owns 464,582 shares in the company, valued at approximately $1,096,413.52. This represents a 4.35 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Raju Mohan bought 261,752 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was bought at an average price of $2.01 per share, for a total transaction of $526,121.52. Following the purchase, the chief executive officer now owns 2,175,028 shares in the company, valued at approximately $4,371,806.28. This represents a 13.68 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 630,000 shares of company stock worth $1,262,415 in the last quarter. 18.18% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Ventyx Biosciences

Institutional investors have recently modified their holdings of the stock. Deerfield Management Company L.P. Series C raised its stake in Ventyx Biosciences by 64.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock worth $13,466,000 after acquiring an additional 2,287,570 shares during the period. Sio Capital Management LLC raised its stake in Ventyx Biosciences by 153.2% during the third quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock worth $4,299,000 after acquiring an additional 1,193,024 shares during the period. Vestal Point Capital LP raised its stake in Ventyx Biosciences by 31.2% during the third quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock worth $3,760,000 after acquiring an additional 410,000 shares during the period. Geode Capital Management LLC raised its stake in Ventyx Biosciences by 5.9% during the third quarter. Geode Capital Management LLC now owns 1,391,702 shares of the company’s stock worth $3,034,000 after acquiring an additional 77,350 shares during the period. Finally, State Street Corp raised its stake in Ventyx Biosciences by 0.8% during the third quarter. State Street Corp now owns 1,187,650 shares of the company’s stock worth $2,589,000 after acquiring an additional 9,783 shares during the period. Institutional investors and hedge funds own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.